A Study Comparing Sirukumab (CNTO 136) Monotherapy With Adalimumab (HUMIRA®) Monotherapy in the Treatment of Active Rheumatoid Arthritis
Public ClinicalTrials.gov record NCT02019472. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-blind, Parallel Group Study of Sirukumab Monotherapy Compared With HUMIRA® Monotherapy Administered Subcutaneously, in Subjects With Active Rheumatoid Arthritis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective is to investigate the efficacy of sirukumab monotherapy compared with adalimumab monotherapy in biologic naïve subjects with active rheumatoid arthritis who are intolerant to methotrexate, who are considered inappropriate for treatment with methotrexate or who are inadequate responders to methotrexate.
Study identification
- NCT ID
- NCT02019472
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 559 participants
Conditions and interventions
Conditions
Interventions
- adalimumab 40 mg Biological
- sirukumab 100 mg Biological
- sirukumab 50 mg Biological
- Placebo Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 4, 2014 (Actual)
- Primary completion
- Aug 17, 2016 (Actual)
- Completion
- Aug 17, 2016 (Actual)
- Last update posted
- Oct 26, 2017
2014 – 2016
United States locations
- U.S. sites
- 42
- U.S. states
- 18
- U.S. cities
- 42
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | — | — |
| Not listed | Phoenix | Arizona | — | — |
| Not listed | Arvin | California | — | — |
| Not listed | El Cajon | California | — | — |
| Not listed | Huntington Beach | California | — | — |
| Not listed | Pleasanton | California | — | — |
| Not listed | Thousand Oaks | California | — | — |
| Not listed | Tustin | California | — | — |
| Not listed | Whittier | California | — | — |
| Not listed | Newark | Delaware | — | — |
| Not listed | Aventura | Florida | — | — |
| Not listed | Dunedin | Florida | — | — |
| Not listed | Miami | Florida | — | — |
| Not listed | New Port Richey | Florida | — | — |
| Not listed | Palm Harbor | Florida | — | — |
| Not listed | Plantation | Florida | — | — |
| Not listed | Tampa | Florida | — | — |
| Not listed | Kansas City | Kansas | — | — |
| Not listed | Elizabethtown | Kentucky | — | — |
| Not listed | Paducah | Kentucky | — | — |
| Not listed | Frederick | Maryland | — | — |
| Not listed | Wheaton | Maryland | — | — |
| Not listed | St Louis | Missouri | — | — |
| Not listed | Las Vegas | Nevada | — | — |
| Not listed | Salisbury | North Carolina | — | — |
| Not listed | Wilmington | North Carolina | — | — |
| Not listed | Dayton | Ohio | — | — |
| Not listed | Portland | Oregon | — | — |
| Not listed | Duncansville | Pennsylvania | — | — |
| Not listed | Wexford | Pennsylvania | — | — |
| Not listed | Wyomissing | Pennsylvania | — | — |
| Not listed | Jackson | Tennessee | — | — |
| Not listed | Nashville | Tennessee | — | — |
| Not listed | Austin | Texas | — | — |
| Not listed | Carrollton | Texas | — | — |
| Not listed | Corpus Christi | Texas | — | — |
| Not listed | Cypress | Texas | — | — |
| Not listed | Lubbock | Texas | — | — |
| Not listed | McKinney | Texas | — | — |
| Not listed | Mesquite | Texas | — | — |
| Not listed | Chesapeake | Virginia | — | — |
| Not listed | Clarksburg | West Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 65 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02019472, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 26, 2017 · Synced Oct 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02019472 live on ClinicalTrials.gov.